FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072714677> ?p ?o ?g. }

• W2072714677 endingPage "1370" @default.
• W2072714677 startingPage "1370" @default.
• W2072714677 abstract "Abstract Solid tumor growth requires new blood vessel formation or angiogenesis. Inhibition of angiogenesis as a therapeutic strategy in oncology has been validated by treatments that block vascular endothelial growth factor (VEGF) or its receptors, such as bevacizumab (Avastin®), which is an anti-VEGF antibody that prolongs survival in colorectal, lung and other cancer patients in combination with chemotherapy. However, since not all tumors are sensitive to VEGF blockade and resistance mechanisms to VEGF therapies can develop, inhibition of additional targets may be necessary in order to control tumor growth and achieve better clinical effects. PlGF is a member of the VEGF family that is found only in very low levels under normal physiological conditions, but is up-regulated in almost all major malignant diseases. PlGF expression has shown to correlate with tumor stages and patient survival in breast cancer, CRC and gastric cancer [1-3]. Pre-clinical data support a role for PlGF in tumor angiogenesis, and demonstrate that blocking PlGF can inhibit tumor growth [4]. RO5323441, a humanized IgG1 monoclonal antibody directed against PlGF, has demonstrated anti-tumor activity in human tumor xenograft models in mice, has a benign preclinical toxicology profile and is being developed for the treatment of multiple advanced cancer indications. RO5323441 binds to both PlGF-1 and PlGF-2 in a dose dependent manner, and is not cross-reactive with murine PlGF or human VEGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR −1 with IC50 values of 0.1 and 0.2 nM, respectively. RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. Antitumor activity has been demonstrated in mutliple tumor models including ACHN and Caki-1 renal cell carcinoma and Huh-7, hepatocellular carcinoma xenografts. Inhibition of established tumors ranged from 43-97% with twice weekly dosing. A refractory model of non-small cell lung cancer has also been identified. Studies to understand the mechanism of action and to identify pharmacodynamic markers and have been carried out in ACHN-tumor bearing mice. References 1. Wei SC, Tsao PN, Yu SC, et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut. 2005 May; 54(5):666-72. 2. Parr C, Watkins G, Boulton M et al. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer. 2005 Dec;41(18):2819-27. 3. Chen CN, Hsieh FJ, Cheng YM, et al. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett. 2004 Sep 15;213(1):73-82. 4. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007. 131 : 463-75. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1370." @default.
• W2072714677 created "2016-06-24" @default.
• W2072714677 creator A5005659795 @default.
• W2072714677 creator A5009131648 @default.
• W2072714677 creator A5016975405 @default.
• W2072714677 creator A5022226047 @default.
• W2072714677 creator A5025596555 @default.
• W2072714677 creator A5045016448 @default.
• W2072714677 creator A5053258785 @default.
• W2072714677 creator A5070213969 @default.
• W2072714677 creator A5072240716 @default.
• W2072714677 date "2010-04-01" @default.
• W2072714677 modified "2023-10-14" @default.
• W2072714677 title "Abstract 1370: RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo" @default.
• W2072714677 doi "https://doi.org/10.1158/1538-7445.am10-1370" @default.
• W2072714677 hasPublicationYear "2010" @default.
• W2072714677 type Work @default.
• W2072714677 sameAs 2072714677 @default.
• W2072714677 citedByCount "3" @default.
• W2072714677 countsByYear W20727146772012 @default.
• W2072714677 countsByYear W20727146772020 @default.
• W2072714677 crossrefType "journal-article" @default.
• W2072714677 hasAuthorship W2072714677A5005659795 @default.
• W2072714677 hasAuthorship W2072714677A5009131648 @default.
• W2072714677 hasAuthorship W2072714677A5016975405 @default.
• W2072714677 hasAuthorship W2072714677A5022226047 @default.
• W2072714677 hasAuthorship W2072714677A5025596555 @default.
• W2072714677 hasAuthorship W2072714677A5045016448 @default.
• W2072714677 hasAuthorship W2072714677A5053258785 @default.
• W2072714677 hasAuthorship W2072714677A5070213969 @default.
• W2072714677 hasAuthorship W2072714677A5072240716 @default.
• W2072714677 hasConcept C121608353 @default.
• W2072714677 hasConcept C126322002 @default.
• W2072714677 hasConcept C150903083 @default.
• W2072714677 hasConcept C159654299 @default.
• W2072714677 hasConcept C167734588 @default.
• W2072714677 hasConcept C203014093 @default.
• W2072714677 hasConcept C207001950 @default.
• W2072714677 hasConcept C2776694085 @default.
• W2072714677 hasConcept C2776871010 @default.
• W2072714677 hasConcept C2777025900 @default.
• W2072714677 hasConcept C2777802072 @default.
• W2072714677 hasConcept C2780394083 @default.
• W2072714677 hasConcept C502942594 @default.
• W2072714677 hasConcept C526805850 @default.
• W2072714677 hasConcept C542903549 @default.
• W2072714677 hasConcept C71924100 @default.
• W2072714677 hasConcept C86803240 @default.
• W2072714677 hasConceptScore W2072714677C121608353 @default.
• W2072714677 hasConceptScore W2072714677C126322002 @default.
• W2072714677 hasConceptScore W2072714677C150903083 @default.
• W2072714677 hasConceptScore W2072714677C159654299 @default.
• W2072714677 hasConceptScore W2072714677C167734588 @default.
• W2072714677 hasConceptScore W2072714677C203014093 @default.
• W2072714677 hasConceptScore W2072714677C207001950 @default.
• W2072714677 hasConceptScore W2072714677C2776694085 @default.
• W2072714677 hasConceptScore W2072714677C2776871010 @default.
• W2072714677 hasConceptScore W2072714677C2777025900 @default.
• W2072714677 hasConceptScore W2072714677C2777802072 @default.
• W2072714677 hasConceptScore W2072714677C2780394083 @default.
• W2072714677 hasConceptScore W2072714677C502942594 @default.
• W2072714677 hasConceptScore W2072714677C526805850 @default.
• W2072714677 hasConceptScore W2072714677C542903549 @default.
• W2072714677 hasConceptScore W2072714677C71924100 @default.
• W2072714677 hasConceptScore W2072714677C86803240 @default.
• W2072714677 hasIssue "8_Supplement" @default.
• W2072714677 hasLocation W20727146771 @default.
• W2072714677 hasOpenAccess W2072714677 @default.
• W2072714677 hasPrimaryLocation W20727146771 @default.
• W2072714677 hasRelatedWork W1868293759 @default.
• W2072714677 hasRelatedWork W1967397018 @default.
• W2072714677 hasRelatedWork W2097382995 @default.
• W2072714677 hasRelatedWork W2107314204 @default.
• W2072714677 hasRelatedWork W2133667957 @default.
• W2072714677 hasRelatedWork W2161089579 @default.
• W2072714677 hasRelatedWork W2502269149 @default.
• W2072714677 hasRelatedWork W2580213734 @default.
• W2072714677 hasRelatedWork W3004940953 @default.
• W2072714677 hasRelatedWork W4235333461 @default.
• W2072714677 hasVolume "70" @default.
• W2072714677 isParatext "false" @default.
• W2072714677 isRetracted "false" @default.
• W2072714677 magId "2072714677" @default.
• W2072714677 workType "article" @default.